LNTH Q1 2021 Earnings — Lantheus Holdings, Inc. Revenue & Financial Results | Market Cap Arena

LNTHLantheus Holdings, Inc.

$5B

Q1 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$93M+2.0% YoY

Gross Profit

$41M44.4% margin

Operating Income

$16M16.9% margin

Net Income

$9M9.7% margin

EPS (Diluted)

$0.13

QoQ Revenue Growth

-1.7%

Cash Flow

Operating Cash Flow

$10M

Free Cash Flow

$7M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$843M

Total Liabilities

$315M

Stockholders' Equity

$528M

Cash & Equivalents

$69M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$93M	$91M	+2.0%
Gross Profit	$41M	$38M	+8.0%
Operating Income	$16M	$7M	+119.3%
Net Income	$9M	$3M	+169.9%

Revenue Segments

Product

$87M32%

Total Precision Diagnostics

$86M32%

DEFINITY

$56M21%

Techne Lite

$23M8%

Other Precision Diagnostics

$7M3%

Strategic Partnerships And Other

$5M2%

License and Royalty Revenues

$5M2%

Radiopharmaceutical Oncology

$2M1%